Put Option on ACAD 9/9/19
Updated
Bought 
ACAD $20 strike puts with expiration on 1/15/21.
I am calling this a short squeeze. Research published today shows Nuplazid as a promising drug for Parkinsons induced Psychosis. Looking into the research paper, they used a "one sided" P-Value test, which negates the reverse end of the gausian curve. I think they are doctoring the study after mortality rates increased from last trial. Drug still comes with this warning label.
P-Value very significant, but I think it is suspicious.
WARNING: INCREASED MORTALITY IN ELDERLY PATIENTS WITH DEMENTIA-RELATED PSYCHOSIS
Elderly patients with dementia-related psychosis treated with antipsychotic drugs are at an increased risk of death.
NUPLAZID is not approved for the treatment of patients with dementia-related psychosis unrelated to the hallucinations and delusions associated with Parkinson’s disease psychosis.
Looking to hold for a week to a month, once the price breaks down. I view this as non news and a short squeeze.
Article doesn't even mention which carriers will reimburse the drug and etc.
ACAD $20 strike puts with expiration on 1/15/21.I am calling this a short squeeze. Research published today shows Nuplazid as a promising drug for Parkinsons induced Psychosis. Looking into the research paper, they used a "one sided" P-Value test, which negates the reverse end of the gausian curve. I think they are doctoring the study after mortality rates increased from last trial. Drug still comes with this warning label.
P-Value very significant, but I think it is suspicious.
WARNING: INCREASED MORTALITY IN ELDERLY PATIENTS WITH DEMENTIA-RELATED PSYCHOSIS
Elderly patients with dementia-related psychosis treated with antipsychotic drugs are at an increased risk of death.
NUPLAZID is not approved for the treatment of patients with dementia-related psychosis unrelated to the hallucinations and delusions associated with Parkinson’s disease psychosis.
Looking to hold for a week to a month, once the price breaks down. I view this as non news and a short squeeze.
Article doesn't even mention which carriers will reimburse the drug and etc.
Note
Cost $1.90 As of 9/9/19, looking for 20% potential profit.
Disclaimer
The information and publications are not meant to be, and do not constitute, financial, investment, trading, or other types of advice or recommendations supplied or endorsed by TradingView. Read more in the Terms of Use.